logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Novartis' Revolution: A new dimension and Prohost expectations

The Market is Outperforming Today. There is important news today about Novartis; part of which we are posting now. There is still more news related to Novartis as well as other biotech and biopharmaceutical companies. All will be in the...

Read More

April 1, 2019

0

The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals.

The Amgen/Novartis Story In May 2018 Amgen ( AMGN ) & Novartis ( NVS ) announced that their novel migraine drug Aimovig™ was granted FDA approval for adults. Aimovig is the first and only FDA-approved migraine treatment designed to specifically...

Read More

April 8, 2019

0

Why Investors Caused a Selloff of Alnylam’s Stock

Alnylam (ALN)  is probably experiencing a stock selloff following the announcement of successful results from  Pfizer’s (PFE)  drug tafamidis.    Indeed, results from Phase 3 ATT-ACT clinical trial demonstrate that tafamidis succeeded in treating Transthyretin Cardiomyopathy,  a  subtype of TTR amyloidosis...

Read More

April 2, 2018

0

Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

Amgen and UDB Granted FDA Approval of Evenity™ Amgen ( AMGN ) and U CB Pharmaceuticals ( UCB ) announced that the U.S. Food and Drug Administration (FDA) has granted approval of Evenity™(romosozumab-aqqg) for osteoporosis in postmenopausal women at high risk...

Read More

April 10, 2019

0

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If  They Sell the Best of the Best  Biotechnology Firms Only Because the Market Is Weird   Even if one is scared and feels he should sell shares, he must be wise...

Read More

April 5, 2018

0

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

NOVARTIS TO ACQUIRE AVEXIS A few months ago,  Novartis (NVS)  CEO agreed to cash out of the company’s consumer health joint venture with   GlaxoSmithKline (GSK) , which brought in cash intended to further improve and expand Novartis’ pipeline. Here...

Read More

April 10, 2018

0

RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

RegenxBio Rebounding RegenxBio ( RGNX ) has the viral vectors which could safely deliver genes into the cells. The firm has improved the adeno-associated viruses making them safe and effective gene delivery vehicles. One of the three currently approved gene...

Read More

October 15, 2019

0

Illumina’s Contribution to Practicing Precision Medicine

When we reiterated that  Illumina (ILMN)  is the engine of the biotechnology evolution we meant it. We have to add, though, that the evolution made possible by Illumina’s sequencers and next-generation sequencing (NGS) engine is tremendously improving research and medical...

Read More

April 11, 2018

0

Novartis: More promising data from a Phase 3 trial with AveXis' gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis Inc., a Novartis ( NVS ) company, announced positive interim data from its Phase 3 STR1VE trial of Zolgensma ®  ( onasemnogene abeparvovec - xio...

Read More

April 17, 2019

0

Inspiring News from a Small Firm

Following the news announcing that  Amgen’s (AMGN)  drug KYPROLIS ®  (carfilzomib) extended the lives of patients with relapsed or refractory multiple myeloma in combination with lenalidomide + dexamethasone, we got news from a small company called  Karyopharm Therapeutics (KPTI)  announcing...

Read More

May 2, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 71
  • 72
  • 73
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy